Preclinical evaluation of the dual specific Src/Abl kinase inhibitor AZD0530 in lung cancer

• Published in: Journal of clinical oncology Vol. 24; no. 18_suppl; p. 13108
• Main Authors: Gautschi, O., Purnell, P., Evans, C. P., Yang, J. C., Holland, W. S., Bold, R. J., Virudachalam, S., Lara, P. N., Gandara, D. R., Gumerlock, P. H.
• Format: Journal Article
• Language: English; Japanese
• Published: 20.06.2006

Abstract only 13108 Background: AZD0530 is a highly selective, orally available, dual specific Src/Abl kinase inhibitor in clinical development. We tested this agent in multiple lung cancer cell lines in vitro. We hypothesized that activity of AZD0530 may depend on the level of activated (pY416-)Src...